ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2228

Has MRI an Added Value over Serum Creatine Kinase Measurement in Myositis?

Nicolo Pipitone1, Antonella Notarnicola2, Giulio Zuccoli3, Lucia Spaggiari4, Gabriele Levrini5, Arnaldo Scardapane6, Florenzo Iannone2, Giovanni Lapadula2 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, 3Children's Hospital of Pittsburgh, Pittsburgh, PA, 4Radiology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 5Arcispedale S Maria Nuova, Reggio Emilia, Italy, 6Radiology, University of Bari, Bari, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: MRI and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy

Session Type: Abstract Submissions (ACR)

Background/Purpose

MRI is widely used to assess inflammation in myositis. Muscle edema on short tau inversion recovery (STIR) sequences is thought to reflect active inflammation. However, it is unclear whether MRI has an added value over the cheaper, easier-to-obtain measurement of serum creatine kinase (sCK) levels. Our aim was to assess the concordance between sCK and MRI edema in a cohort of patients with myositis at their first presentation to our centers.

Methods

We enrolled in 2 Rheumatology centers 73 patients, 34 with dermatomyositis (DM) and 39 with polymyositis (PM) diagnosed according to Bohan and Peter criteria. In all patients, sCK were measured and MRI sequences were acquired at the same time. MRI edema (1= present, 0= absent) was assessed bilaterally in 17 thigh and pelvic floor muscles. An MRI composite edema score (0-17) was calculated by adding the separate scores bilaterally and dividing them by two as described elsewhere (1). sCK was considered positive if values were above the upper limit of normal (190 U/l), while MRI was considered positive if the edema score was at least 1. The (single measures) intraclass correlation coefficient (ICC) between the Radiologists involved was 0.78. Muscle strength was measured by MMT (manual muscle testing) and graded according to the Medical Research Council extended scale (0-5). The ICC between the 2 physicians performing the MMT was 0.8.

Results

sCK and MRI were discordant in 47% of patients with myositis, more frequently in DM (59%) than in PM (39%). 56% of patients with DM, but only 15% of those with PM had a positive MRI with normal sCK.

 

All patients (=73)

DM (=34)

PM (=39)

sCK+ MRI+

32

11

21

sCK- MRI-

7

3

4

sCK + MRI-

9

1

8

sCK- MRI+

25

19

6

There was a significant correlation between MRI score and muscle strength of the hip flexors (Spearman’s rho 0.26, p 0.028) but not between MRI score and overall muscle strength. 

Conclusion

MRI is a useful tool to assess disease activity in myositis, especially in DM, where it can be identify a sizeable number of patients who have normal sCK. Further studies of larger cohorts are warranted to confirm our findings.

References: (1) Clin Exp Rheumatol 2012; 30:570-3


Disclosure:

N. Pipitone,
None;

A. Notarnicola,
None;

G. Zuccoli,
None;

L. Spaggiari,
None;

G. Levrini,
None;

A. Scardapane,
None;

F. Iannone,
None;

G. Lapadula,
None;

C. Salvarani,

Novartis Pharma AG,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/has-mri-an-added-value-over-serum-creatine-kinase-measurement-in-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology